Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

6(75.0%)

Early Phase 1

1(12.5%)

Phase 2

1(12.5%)

8Total

Phase 1(6)

Early Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06823167Phase 1Recruiting

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Role: lead

NCT07505771Early Phase 1Not Yet Recruiting

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Role: lead

NCT06841315Phase 1Completed

A Varegacestat Hepatic Impairment Study

Role: lead

NCT04871282Phase 2Active Not Recruiting

A Study of AL102 in Patients With Progressing Desmoid Tumors

Role: lead

NCT06845852Phase 1Completed

A Phase 1 Mass Balance Study of Varegacestat

Role: lead

NCT06855264Phase 1Completed

A Cardiac Liability Study of Varegacestat in Healthy Participants

Role: lead

NCT06677996Phase 1Completed

A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants

Role: lead

NCT05429021Phase 1Terminated

IMM-BCP-01 in Mild to Moderate COVID-19

Role: lead

All 8 trials loaded